Highlights 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.292 ^USD	+0.76%		-7.27%	-71.37%

May. 30	60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	CI
May. 20	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	May. 30	CI
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	May. 20	CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	May. 02	CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	Mar. 14	CI
60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDA	Jan. 22	DJ
60 Degrees Pharma Plans Tafenoquine Study After FDA Meeting	Jan. 22	DJ
60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine	Jan. 22	CI
60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	Dec. 26	CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
60 Degrees Pharmaceuticals, Inc. Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	Nov. 15	CI
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases	23-10-12	CI
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	23-09-19	DJ
60 Degrees Pharma withdraws mid-stage study application for COVID drug	23-09-18	RE
60 Degrees Withdraws COVID Phase IIB Investigational New Drug Application; Shares Drop After-Hours	23-09-18	MT
60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements	23-09-18	CI
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria	23-08-22	CI
60 Degrees Pharmaceuticals, Inc. Registers ACLR8-LR	23-08-15	CI
60 Degrees Pharmaceuticals Receives Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects	23-07-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Highlights

Filters